Multivariable logistic regression for risks of symptom domain prevalence and poor HRQOL between overall HSCT and conventional therapy survivors by accounting for chronic health conditions
| Risk factors . | Sensationabnormalities . | Motor/movementproblems . | Cardiacsymptoms . | Pulmonarysymptoms . | Pain . | Fatigue . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT vs conventional therapy survivors* | 1.2 (0.8-2.0) | 1.0 (0.5-1.9) | 0.9 (0.4-1.7) | 1.0 (0.5-1.9) | 0.5 (0.3-0.8) | 0.7 (0.3-1.3) |
| Age at survey | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) | 1.0 (1.0- 1.1) | 1.1 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.3 (1.1-1.7) | 1.5 (1.0-2.1) | 2.4 (1.7-3.5) | 1.5 (1.0-2.0) | 1.7 (1.3-2.3) | 1.9 (1.4-2.5) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.4 (1.0-2.0) | 1.0 (0.6-1.5) | 0.9 (0.6-1.4) | 0.8 (0.5-1.2) | 1.3 (0.9-1.8) | 1.1 (0.7-1.7) |
| Education | ||||||
| <College vs ≥college* | 1.3 (1.0-1.8) | 1.7 (1.2-2.6) | 1.5 (1.1-2.3) | 1.6 (1.1-2.3) | 1.8 (1.3-2.4) | 2.3 (1.6-3.3) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 1.0 (0.8-1.4) | 1.6 (1.1-2.3) | 1.0 (0.7-1.4) | 1.7 (1.2-2.4) | 0.8 (0.6-1.1) | 0.9 (0.7-1.3) |
| Cardiovascular† | 1.3 (0.8-1.9) | 1.2 (0.7-2.1) | 3.0 (1.8-4.9) | 1.2 (0.7-2.1) | 1.5 (0.9-2.7) | 1.2 (0.7-2.0) |
| Endocrine† | 1.4 (1.1-1.8) | 1.9 (1.4-2.7) | 1.0 (0.7-1.4) | 1.2 (0.9-1.8) | 1.4 (1.0-1.8) | 1.5 (1.1-2.1) |
| Gastrointestinal† | 1.3 (0.9-1.9) | 1.4 (0.9-2.3) | 1.2 (0.7-2.0) | 1.5 (0.9-2.4) | 1.3 (0.8-2.1) | 1.2 (0.7-1.9) |
| Neurology† | 1.9 (1.2-3.1) | 3.3 (2.0-5.5) | 1.4 (0.8-2.5) | 1.9 (1.1-3.2) | 1.3 (0.8-2.4) | 1.9 (1.2-3.2) |
| Ocular† | 2.2 (1.0-4.8) | 2.7 (1.1-6.9) | 1.0 (0.3-2.9) | 0.5 (0.1-1.7) | 2.3 (0.9-6.0) | 2.3 (0.9-5.6) |
| Pulmonary† | 1.0 (0.6-1.7) | 0.9 (0.4-1.7) | 3.0 (1.7-5.3) | 2.5 (1.4-4.3) | 1.8 (0.9-3.6) | 1.0 (0.5-1.8) |
| Reproductive† | 1.3 (1.0-1.8) | 0.8 (0.5-1.2) | 0.9 (0.6-1.4) | 1.0 (0.6-1.5) | 1.4 (1.0-2.0) | 1.4 (1.0-2.1) |
| Risk factors . | Sensationabnormalities . | Motor/movementproblems . | Cardiacsymptoms . | Pulmonarysymptoms . | Pain . | Fatigue . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT vs conventional therapy survivors* | 1.2 (0.8-2.0) | 1.0 (0.5-1.9) | 0.9 (0.4-1.7) | 1.0 (0.5-1.9) | 0.5 (0.3-0.8) | 0.7 (0.3-1.3) |
| Age at survey | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) | 1.0 (1.0- 1.1) | 1.1 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.3 (1.1-1.7) | 1.5 (1.0-2.1) | 2.4 (1.7-3.5) | 1.5 (1.0-2.0) | 1.7 (1.3-2.3) | 1.9 (1.4-2.5) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.4 (1.0-2.0) | 1.0 (0.6-1.5) | 0.9 (0.6-1.4) | 0.8 (0.5-1.2) | 1.3 (0.9-1.8) | 1.1 (0.7-1.7) |
| Education | ||||||
| <College vs ≥college* | 1.3 (1.0-1.8) | 1.7 (1.2-2.6) | 1.5 (1.1-2.3) | 1.6 (1.1-2.3) | 1.8 (1.3-2.4) | 2.3 (1.6-3.3) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 1.0 (0.8-1.4) | 1.6 (1.1-2.3) | 1.0 (0.7-1.4) | 1.7 (1.2-2.4) | 0.8 (0.6-1.1) | 0.9 (0.7-1.3) |
| Cardiovascular† | 1.3 (0.8-1.9) | 1.2 (0.7-2.1) | 3.0 (1.8-4.9) | 1.2 (0.7-2.1) | 1.5 (0.9-2.7) | 1.2 (0.7-2.0) |
| Endocrine† | 1.4 (1.1-1.8) | 1.9 (1.4-2.7) | 1.0 (0.7-1.4) | 1.2 (0.9-1.8) | 1.4 (1.0-1.8) | 1.5 (1.1-2.1) |
| Gastrointestinal† | 1.3 (0.9-1.9) | 1.4 (0.9-2.3) | 1.2 (0.7-2.0) | 1.5 (0.9-2.4) | 1.3 (0.8-2.1) | 1.2 (0.7-1.9) |
| Neurology† | 1.9 (1.2-3.1) | 3.3 (2.0-5.5) | 1.4 (0.8-2.5) | 1.9 (1.1-3.2) | 1.3 (0.8-2.4) | 1.9 (1.2-3.2) |
| Ocular† | 2.2 (1.0-4.8) | 2.7 (1.1-6.9) | 1.0 (0.3-2.9) | 0.5 (0.1-1.7) | 2.3 (0.9-6.0) | 2.3 (0.9-5.6) |
| Pulmonary† | 1.0 (0.6-1.7) | 0.9 (0.4-1.7) | 3.0 (1.7-5.3) | 2.5 (1.4-4.3) | 1.8 (0.9-3.6) | 1.0 (0.5-1.8) |
| Reproductive† | 1.3 (1.0-1.8) | 0.8 (0.5-1.2) | 0.9 (0.6-1.4) | 1.0 (0.6-1.5) | 1.4 (1.0-2.0) | 1.4 (1.0-2.1) |
| Risk factors . | Nausea . | Memory problems . | Anxiety . | Depression . | PCS (score ≤40) . | MCS (score ≤40) . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT vs conventional therapy survivors* | 0.8 (0.4-1.6) | 1.2 (0.8-2.1) | 0.8 (0.5-1.4) | 0.7 (0.4-1.2) | 1.0 (0.5-2.0) | 0.8 (0.5-1.5) |
| Age at survey | 1.0 (1.0-1.0) | 1.0 (0.9-1.0) | 1.0 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.1-1.1) | 1.1 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.9 (1.4-2.7) | 1.5 (1.2-2.0) | 1.3 (1.1-1.7) | 1.3 (1.0-1.6) | 1.5 (1.0-2.1) | 1.5 (1.1-2.0) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.1 (0.7-1.7) | 1.8 (1.2-2.6) | 1.1 (0.8-1.6) | 0.9 (0.7-1.3) | 1.0 (0.6-1.5) | 1.1 (0.7-1.5) |
| Education | ||||||
| <College vs ≥college* | 1.4 (1.0-2.0) | 2.1 (1.5-2.8) | 1.3 (1.0-1.7) | 1.5 (1.1-2.0) | 2.6 (1.7-4.0) | 2.1 (1.5-3.0) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 0.9 (0.6-1.3) | 1.5 (1.1-2.0) | 1.3 (1.0-1.7) | 2.0 (1.5-2.6) | 1.4 (0.9-2.0) | 1.6 (1.2-2.2) |
| Cardiovascular† | 1.2 (0.7-2.0) | 0.9 (0.6-1.5) | 1.1 (0.7-1.7) | 1.6 (1.0-2.4) | 2.8 (1.7-4.6) | 1.6 (1.0-2.5) |
| Endocrine† | 1.6 (1.1-2.3) | 1.2 (0.9-1.6) | 1.1 (0.9-1.4) | 1.4 (1.1-1.9) | 1.3 (0.9-1.9) | 1.4 (1.0-1.8) |
| Gastrointestinal† | 2.0 (1.2-3.1) | 1.1 (0.7-1.7) | 1.4 (1.0-2.1) | 1.3 (0.9-1.9) | 1.3 (0.8-2.1) | 0.9 (0.6-1.4) |
| Neurology† | 1.2 (0.6-2.2) | 2.2 (1.4-3.5) | 1.0 (0.6-1.6) | 1.3 (0.8-2.1) | 2.6 (1.6-4.4) | 1.6 (1.0-2.6) |
| Ocular† | 1.6 (0.6-4.2) | 0.7 (0.3-1.7) | 0.7 (0.3-1.6) | 0.6 (0.2-1.5) | 2.1 (0.8-5.4) | 0.9 (0.3-2.2) |
| Pulmonary† | 1.5 (0.8-2.7) | 2.0 (1.2-3.3) | 1.0 (0.6-1.7) | 1.1 (0.6-1.9) | 2.7 (1.6-4.8) | 1.5 (0.9-2.6) |
| Reproductive† | 1.5 (1.0-2.2) | 1.1 (0.8-1.6) | 1.1 (0.8-1.5) | 1.2 (0.9-1.7) | 1.3 (0.9-1.9) | 0.9 (0.6-1.3) |
| Risk factors . | Nausea . | Memory problems . | Anxiety . | Depression . | PCS (score ≤40) . | MCS (score ≤40) . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT vs conventional therapy survivors* | 0.8 (0.4-1.6) | 1.2 (0.8-2.1) | 0.8 (0.5-1.4) | 0.7 (0.4-1.2) | 1.0 (0.5-2.0) | 0.8 (0.5-1.5) |
| Age at survey | 1.0 (1.0-1.0) | 1.0 (0.9-1.0) | 1.0 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.1-1.1) | 1.1 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.9 (1.4-2.7) | 1.5 (1.2-2.0) | 1.3 (1.1-1.7) | 1.3 (1.0-1.6) | 1.5 (1.0-2.1) | 1.5 (1.1-2.0) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.1 (0.7-1.7) | 1.8 (1.2-2.6) | 1.1 (0.8-1.6) | 0.9 (0.7-1.3) | 1.0 (0.6-1.5) | 1.1 (0.7-1.5) |
| Education | ||||||
| <College vs ≥college* | 1.4 (1.0-2.0) | 2.1 (1.5-2.8) | 1.3 (1.0-1.7) | 1.5 (1.1-2.0) | 2.6 (1.7-4.0) | 2.1 (1.5-3.0) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 0.9 (0.6-1.3) | 1.5 (1.1-2.0) | 1.3 (1.0-1.7) | 2.0 (1.5-2.6) | 1.4 (0.9-2.0) | 1.6 (1.2-2.2) |
| Cardiovascular† | 1.2 (0.7-2.0) | 0.9 (0.6-1.5) | 1.1 (0.7-1.7) | 1.6 (1.0-2.4) | 2.8 (1.7-4.6) | 1.6 (1.0-2.5) |
| Endocrine† | 1.6 (1.1-2.3) | 1.2 (0.9-1.6) | 1.1 (0.9-1.4) | 1.4 (1.1-1.9) | 1.3 (0.9-1.9) | 1.4 (1.0-1.8) |
| Gastrointestinal† | 2.0 (1.2-3.1) | 1.1 (0.7-1.7) | 1.4 (1.0-2.1) | 1.3 (0.9-1.9) | 1.3 (0.8-2.1) | 0.9 (0.6-1.4) |
| Neurology† | 1.2 (0.6-2.2) | 2.2 (1.4-3.5) | 1.0 (0.6-1.6) | 1.3 (0.8-2.1) | 2.6 (1.6-4.4) | 1.6 (1.0-2.6) |
| Ocular† | 1.6 (0.6-4.2) | 0.7 (0.3-1.7) | 0.7 (0.3-1.6) | 0.6 (0.2-1.5) | 2.1 (0.8-5.4) | 0.9 (0.3-2.2) |
| Pulmonary† | 1.5 (0.8-2.7) | 2.0 (1.2-3.3) | 1.0 (0.6-1.7) | 1.1 (0.6-1.9) | 2.7 (1.6-4.8) | 1.5 (0.9-2.6) |
| Reproductive† | 1.5 (1.0-2.2) | 1.1 (0.8-1.6) | 1.1 (0.8-1.5) | 1.2 (0.9-1.7) | 1.3 (0.9-1.9) | 0.9 (0.6-1.3) |